Free tool
FAERS Monitor: Intuniv
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022037 or its brand name (Intuniv, Guanfacine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
7,123
Serious
4,202
59% of reports
Hospitalization
1,691
Death reported
218
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective740
- off label use588
- somnolence433
- aggression362
- fatigue311
- hypotension277
- dizziness264
- headache255
- intentional overdose252
- suicidal ideation252
- insomnia250
- anxiety248
- bradycardia248
- nausea235
- toxicity to various agents217
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2005 | 1 |
| 2006 | 4 |
| 2007 | 3 |
| 2008 | 1 |
| 2009 | 10 |
| 2010 | 101 |
| 2011 | 202 |
| 2012 | 178 |
| 2013 | 201 |
| 2014 | 315 |
| 2015 | 486 |
| 2016 | 457 |
| 2017 | 467 |
| 2018 | 468 |
| 2019 | 476 |
| 2020 | 473 |
| 2021 | 485 |
| 2022 | 537 |
| 2023 | 586 |
| 2024 | 604 |
| 2025 | 536 |
| 2026 | 532 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,036 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| aggressionSignal | 362 | 21.5 | 19.4 | 7,023 |
| bradycardiaSignal | 248 | 13.9 | 12.3 | 2,943 |
| intentional overdoseSignal | 252 | 11.6 | 10.3 | 2,439 |
| suicidal ideationSignal | 252 | 8.1 | 7.2 | 1,576 |
| somnolenceSignal | 433 | 6.4 | 5.8 | 1,966 |
| hypotensionSignal | 277 | 4.1 | 3.6 | 647 |
| toxicity to various agentsSignal | 217 | 3.8 | 3.3 | 449 |
| insomniaSignal | 250 | 2.8 | 2.5 | 285 |
| anxietySignal | 248 | 2.6 | 2.3 | 240 |
| off label use | 588 | 2.0 | 1.8 | 298 |
| drug ineffective | 740 | 1.7 | 1.5 | 206 |
| dizziness | 264 | 1.6 | 1.4 | 54 |
| headache | 255 | 1.2 | 1.1 | 9 |
| fatigue | 311 | 1.2 | 1.1 | 9 |
| nausea | 235 | 0.9 | 0.8 | 4 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.